Evolution of the Average Target: Charles River Laboratories International, Inc.

Evolution of the Target Price: Charles River Laboratories International, Inc.

Changes in Analyst Recommendations: Charles River Laboratories International, Inc.

8fc0df46791a2c95ed1b662aa.2FhdEoGlkUfQZuE5afyF-cpOX-EC3412FA6Em1OvNd4.j2ozX7PK5A-fV6xBIpvcs_0-F6MwscQOY2_DqDvJYpCqbSxV887EFIE5ig~85cab5d39f91bd9615076d9a8e508fb3
09-17 Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating MT
09-11 Evercore ISI Adjusts PT on Charles River Laboratories International to $320 From $300, Maintains Outperform Rating MT
08-10 TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating MT
08-10 Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating MT
08-06 Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220 MT
08-06 RBC Adjusts PT on Charles River Laboratories International to $282 From $215, Keeps Outperform Rating MT
08-06 Deutsche Bank Adjusts Charles River Laboratories International PT to $300 From $260, Maintains Buy Rating MT
08-06 Analyst recommendations: AppLovin, Emerson Electric, Roblox, Flutter Entertainment, HubSpot... Zonebourse
08-06 JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180 MT
07-20 Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… Zonebourse
07-13 BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 MT
07-13 Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating MT
07-13 Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating MT
07-09 Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
07-07 Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
07-01 Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating MT
06-18 Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating MT
06-17 Charles River Laboratories Shares Rise After Morgan Stanley Upgrade MT
06-17 Morgan Stanley Upgrades Charles River Laboratories International to Overweight From Equal Weight, Adjusts PT to $220 From $185 MT
06-05 Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says MT
04-14 Charles River Laboratories Positioned as 'Leading' CRO as Preclinical R&D Inflection Nears, RBC Says MT
04-14 Barclays Adjusts Price Target on Charles River Laboratories International to $210 From $200, Maintains Overweight Rating MT
04-14 RBC Initiates Charles River Laboratories International at Outperform With $215 Price Target MT
04-08 Baird Raises Price Target on Charles River Laboratories International to $200 From $197, Maintains Outperform Rating MT
03-09 Baird Adjusts Price Target on Charles River Laboratories International to $197 From $193 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+2.12%
+25.4%
+2.99%
+31.36%
+18.36%
+47.62%
-6.79%
+31.39%
-7.45%
-12.14%
Average +13.29%
Weighted average by Cap. +17.59%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
279.01USD
Average target price
284.93USD
Spread / Average Target
+2.12%
High Price Target
320.00USD
Spread / Highest target
+14.69%
Low Price Target
145.00USD
Spread / Lowest Target
-48.03%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA
  1. Stock Market
  2. Stocks
  3. CRL Stock
  4. Consensus Charles River Laboratories International, Inc.
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!